FR EN MAIN NAVIGATION COMPANY SCIENCE PRODUCTS PARTNERING INVESTORS MEDIA CAREERS Home Contact CONTACT 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USA Your Name Your Email Subject Category - Select - Business development Corporate communication Investor Relations Press relations Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. What code is in the image? Enter the characters shown in the image. Get new captcha! Send message Footer Contact Location Legal Info Terms of use Privacy Notice Cookies notice General Conditions of Purchase Search Search Follow us Stay in touch Subscribe to our newsletter Contact us Location 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30 Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USA

FR EN MAIN NAVIGATION COMPANY SCIENCE PRODUCTS PARTNERING INVESTORS MEDIA CAREERS IPH5201 PARTNERED WITH ASTRAZENECA | PHASE 1 | ADVANCED SOLID TUMORS Home Products IPH5201 IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway. CD39 is an extracellular enzyme that is expressed in the tumor microenvironment, on both tumor infiltrating cells and stromal cells in several cancer types. CD39 inhibits the immune system by degrading adenosine tripohsphate (ATP) into adenosine monophosphate (AMP), that is then further degraded into adenosine by CD73. By promoting the accumulation of immune-stimulating ATP, and preventing the production of immune-suppressive adenosine, the blockade of CD39 may stimulate anti-tumor activity. Mechanism of action of IPH5201 Collaboration with AstraZeneca Clinical Development Publications, posters and presentations View publications Main menu Pipeline overview Clinical trials ------------------ Lacutamab Monalizumab Avdoralimab IPH5201 IPH5301 IPH6101 IPH62 LATEST NEWS ON IPH5201 Innate Pharma Third Quarter 2021 Report November 16, 2021 Innate Pharma reports Full Year 2020 financial results and business update March 18, 2021 First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors March 10, 2020 all press releases Footer Contact Location Legal Info Terms of use Privacy Notice Cookies notice General Conditions of Purchase Search Search Follow us Stay in touch Subscribe to our newsletter Contact us Location 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30 Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USA